BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential
BofA Securities has given Definium Therapeutics Inc (NASDAQ:DFTX) a "buy" rating and set a target price of $75.00 per share. The company's lead asset, DT120, is an LSD-based drug in pivotal studies for major depressive disorder and generalized anxiety disorder, with recent phase 3 studies showing promising results. BofA analysts believe DT120 could become a preferred option for patients with severe depression and anxiety if the positive trial outcomes are confirmed. The stock is currently trading at $45.28, presenting significant upside potential.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
